Sun.Feb 11, 2024

article thumbnail

Episode 895: Why is glucagon not recommended in the calcium channel blocker poisoning guidelines?

Pharmacy Joe

In this episode, I’ll discuss why glucagon is not recommended in the calcium channel blocker poisoning guidelines. Episode 895: Why is glucagon not recommended in the calcium channel blocker poisoning guidelines? Subscribe on iTunes , Android , or Stitcher Critical Care Medicine has published in 2017 Experts Consensus Recommendations for the Management of Calcium Channel Blocker Poisoning in Adults.

article thumbnail

Deal value increased by 19.2 per cent in Jan 2024, compared to Jan 2023: GlobalData

Express Pharma

In January 2024, the healthcare industry reported 88 deals worth $13.8 billion, compared to the last 12-month average (January 2023 to December 2023) of 85 deals worth $19.3 billion. Deal Date Acquirer (s) Target Deal Value ($M) 8-Jan-24 Boston Scientific Corp (US) Axonics Inc (US) 3,700.0 8-Jan-24 Johnson & Johnson (US) Ambrx Biopharma Inc (US) 2,000.0 23-Jan-24 Sanofi (France) Inhibrx Inc (US) 1,700.0 9-Jan-24 GSK plc (United Kingdom) Aiolos Bio Inc (US) 1,400.0 8-Jan-24 Merck KGaA (German

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pfizer/BioNTech COVID jab to be sold privately in UK

pharmaphorum

MHRA license change means people in GB will be able to buy Pfizer’s COVID-19 vaccine Comirnaty at retail pharmacies from March

article thumbnail

Sun Pharma included in S&P Global Sustainability Yearbook 2024

Express Pharma

Sun Pharmaceutical Industries has been included in the S&P Global Sustainability Yearbook 2024. Within respective industries, this Yearbook aims to distinguish those companies that have demonstrated strengths in corporate sustainability. A company statement informed, “This recognition attests to Sun Pharma’s commitment to incorporate Environmental, Social, and Governance (ESG) principles through focused initiatives across its businesses.

89
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Teething

RX Note

Introduction Teething is the process in which the deciduous teeth (sometimes known as milk teeth or baby teeth) emerge through the gum. Most infants start teething around 6 months of age, but some can start as early as 3 months. Teething continues until the age of 2-3 years. NOTE: Primary tooth exfoliation occur as part of the process of permanent tooth eruption , which usually begins at approximately 6 years of age.

article thumbnail

Novolog Versus Fiasp Insulin Comparison

Med Ed 101

With many insulin formulations on the market, it can be hard to differentiate between similar-acting products and what the best choice may be for our patients. One question raised is what the differences between Novolog versus Fiasp are due to both being insulin aspart formulations. The main difference is right in the name of Fiasp. […] The post Novolog Versus Fiasp Insulin Comparison appeared first on Med Ed 101.

More Trending

article thumbnail

Which pharmaceutical drugs have the most drug patents in Peru?

Drug Patent Watch

This chart shows the drugs with the most patents in Peru. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.… The post Which pharmaceutical drugs have the most drug patents in Peru? appeared first on DrugPatentWatch - Make Better Decisions.

59
article thumbnail

Marijuana: Top Ten Reasons for Descheduling, Rescheduling or Not

FDA Law Blog: Biosimilars

By Larry K. Houck — With apologies to David Letterman, who introduced the first Top Ten List on Late Night with David Letterman on September 18, 1985, we present “Marijuana: Top Ten Reasons for Descheduling, Rescheduling or Not.”* The wide range of assertions supporting or opposing Health and Human Services’ (“HHS’”) recommendation that the Drug Enforcement Administration (“DEA”) reschedule cannabis federally from schedule I to schedule III would lead an outsider to conclude that commenters are